Biofrontera Inc
NASDAQ:BFRI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.562
1.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Biofrontera Inc
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2021-10-14. The firm is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. The company also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 69 full-time employees. The company went IPO on 2021-10-14. The firm is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. The company also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.
Revenue Trends: Q3 revenue was $7 million, down 22% year-over-year due to a lack of buy-in opportunities from price increases, but year-to-date revenue was roughly flat versus 2024.
Q4 Recovery Expected: Management anticipates strong revenue growth in Q4 and remains confident in achieving full-year sales objectives.
Cost Reductions: Cost of revenues fell 58% year-over-year in Q3, thanks to a new royalty structure and reduced transfer pricing with Biofrontera AG.
Profitability Roadmap: The company expects to reach cash flow breakeven in fiscal year 2026, helped by recent capital infusions and the Xepi divestiture.
Product Pipeline Progress: Clinical trials for new Ameluz indications (basal cell carcinoma and acne) are advancing, with data and FDA submissions expected in early 2026.
Strategic Transaction: Acquisition of all U.S. rights for Ameluz and RhodoLED gives Biofrontera full control and is expected to improve gross margins.
Upcoming Price Increase: Management confirmed plans for a price increase before year-end.
